Olema Pharmaceuticals (OLMA) Research & Development (2020 - 2026)
Olema Pharmaceuticals (OLMA) posted quarterly Research & Development of $49.2 million for Q1 2026, up 60.76% year-over-year from $30.6 million in Q1 2025, and up 13.91% quarter-over-quarter from $43.2 million in Q4 2025.
Olema Pharmaceuticals (OLMA) Research & Development (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported Research & Development for 7 consecutive years, with $49.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 60.76% year-over-year to $49.2 million; the TTM figure through Mar 2026 stood at $176.3 million (up 40.75% YoY), while the FY2025 annual figure was $157.7 million, up 26.65% from the prior year.
- Research & Development climbed to $49.2 million in Q1 2026 per OLMA's latest filing, from $43.2 million in the prior quarter.
- Across five years, Research & Development topped out at $49.2 million in Q1 2026 and bottomed at $16.0 million in Q1 2022.
- Historically, Research & Development has averaged $29.4 million across 5 years, with a median of $29.1 million in 2024.
- Annual changes were most pronounced in 2022 — Research & Development soared 127.15% — and 2023, when it plunged 33.51%.
- Olema Pharmaceuticals' Research & Development stood at $21.6 million in 2022, then climbed by 19.87% to $25.9 million in 2023, then gained by 24.84% to $32.3 million in 2024, then surged by 33.81% to $43.2 million in 2025, then increased by 13.91% to $49.2 million in 2026.
- Business Quant data shows OLMA's Research & Development at $49.2 million in Q1 2026, $43.2 million in Q4 2025, and $40.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Olema Pharmaceuticals | 930.10 Mn | 930.10 Mn | - | 57.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 57.79 Mn |
| Mar 31, 2026 | 49.23 Mn |
| Dec 31, 2025 | 43.22 Mn |
| Sep 30, 2025 | 39.95 Mn |
| Jun 30, 2025 | 43.90 Mn |
| Mar 31, 2025 | 30.62 Mn |
| Dec 31, 2024 | 32.30 Mn |
| Sep 30, 2024 | 33.23 Mn |
| Jun 30, 2024 | 29.11 Mn |
| Mar 31, 2024 | 29.88 Mn |
| Dec 31, 2023 | 25.87 Mn |
| Sep 30, 2023 | 19.45 Mn |
| Jun 30, 2023 | 17.99 Mn |
| Mar 31, 2023 | 22.83 Mn |
| Dec 31, 2022 | 21.58 Mn |
| Sep 30, 2022 | 17.63 Mn |
| Jun 30, 2022 | 27.05 Mn |
| Mar 31, 2022 | 16.01 Mn |
| Dec 31, 2021 | 15.98 Mn |
| Sep 30, 2021 | 12.52 Mn |